Business, energy, technology, markets and global industry news from Business News Today

venetoclax

PharmaDeviceNews venetoclax
Representative image illustrating acute myeloid leukemia research, reflecting Amgen’s acquisition of Dark Blue Therapeutics and its push toward first‑in‑class MLLT1/3 protein degradation strategies in AML drug development.
Pharma & Biotech

Can Chipscreen’s AI-discovered CS43158 overcome leukemia drug resistance? China clears human trials

Chipscreen secures China IND clearance for CS43158, targeting FLT3 mutations and resistance pathways in acute myeloid leukemia.

Read More
Representative image: Hematology researchers analyze blood samples as Moleculin’s $MBRX MIRACLE trial reports a 37% blinded composite remission rate in relapsed or refractory acute myeloid leukemia, including patients who previously failed venetoclax.
Pharma & Biotech

New MIRACLE data examine remission after venetoclax failure in relapsed AML

MIRACLE reports a 37% blinded composite remission rate in relapsed AML, including patients who previously failed venetoclax treatment.

Read More
Representative image of hematology research and blood sample analysis, reflecting AbbVie’s long-term Venclexta data in first-line chronic lymphocytic leukemia treatment.
Pharma & Biotech

AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus

Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.

Read More
Pharma & Biotech

Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?

Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.

Read More
Pharma & Biotech

Ficlatuzumab joins Beat AML trial: is AVEO’s c-Met inhibitor ready for broader testing?

AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.

Read More